September 19, 2011
Prolia Gains Indications for Treatment of Bone Loss in Cancer Patients
In men, bone mineral density (BMD) was significantly higher at the lumbar spine in patients treated with Prolia for two years compared with placebo (-1% placebo, +5.6% Prolia; P<0.0001). Additionally, after three years of treatment with Prolia, differences in BMD were 7.9% at the lumbar spine, 5.7% at the (total) hip and 4.9% at the femoral neck and the incidence of new vertebral fractures was 3.9% in the placebo-treated men compared with 1.5% for the Prolia-treated men, representing a relative risk reduction of 62% (P=0.0125). In women, BMD was higher at 12 months at the lumbar spine in patients treated with Prolia as compared with placebo (-0.7% placebo, +4.8% Prolia; P<0.0001). Additionally, after two years of treatment with Prolia differences in BMD were 7.6% at the lumbar spine, 4.7% at the (total) hip and 3.6% at the femoral neck.
Prolia is already indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
For more information call (877) 4-PROLIA or visit www.prolia.com.